{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=MCG&page=16", "query": { "intervention": "MCG", "page": 16 }, "page_size": 10 }, "pagination": { "page": 16, "page_size": 10, "total_count": 3095, "total_pages": 310, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=MCG&page=17&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=MCG&page=15&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-26T07:53:22.351Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03467373", "title": "A Study of Glofitamab in Combination With Rituximab or Obinutuzumab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP), or Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (CHP) in Participants With Non-Hodgkin Lymphomas or With DLBCL", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "B-Cell Lymphoma", "Non-Hodgkin Lymphoma" ], "interventions": [ { "name": "Glofitamab", "type": "DRUG" }, { "name": "Obinutuzumab (G)", "type": "DRUG" }, { "name": "Rituximab (R)", "type": "DRUG" }, { "name": "Tocilizumab", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Vincristine", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Polatuzumab vedotin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 111, "start_date": "2018-03-13", "completion_date": "2024-12-02", "has_results": false, "last_update_posted_date": "2025-01-17", "last_synced_at": "2026-10-26T07:53:22.351Z", "location_count": 3, "location_summary": "Birmingham, Alabama • Charlotte, North Carolina • Philadelphia, Pennsylvania", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Charlotte", "state": "North Carolina" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT03467373" }, { "nct_id": "NCT01421173", "title": "Vorinostat With Gemcitabine, Busulfan, and Melphalan With Stem Cell Transplant (SCT) in Relapsed or Refractory Lymphoid Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Lymphoma" ], "interventions": [ { "name": "Vorinostat", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Busulfan", "type": "DRUG" }, { "name": "Melphalan", "type": "DRUG" }, { "name": "Stem Cell Infusion", "type": "PROCEDURE" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "G-CSF", "type": "DRUG" }, { "name": "Palifermin", "type": "DRUG" }, { "name": "Dexamethasone acetate", "type": "DRUG" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "12 Years to 65 Years" }, "enrollment_count": 78, "start_date": "2011-08", "completion_date": "2015-09", "has_results": false, "last_update_posted_date": "2015-11-18", "last_synced_at": "2026-10-26T07:53:22.351Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01421173" }, { "nct_id": "NCT02573870", "title": "Batefenterol/Fluticasone Furoate in Treatment of Chronic Obstructive Pulmonary Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Pulmonary Disease, Chronic Obstructive" ], "interventions": [ { "name": "Batefenterol + Fluticasone Furoate", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Albuterol", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": null, "sex": "ALL", "summary": "40 Years and older" }, "enrollment_count": 63, "start_date": "2015-12-01", "completion_date": "2016-07-05", "has_results": true, "last_update_posted_date": "2020-07-21", "last_synced_at": "2026-10-26T07:53:22.351Z", "location_count": 10, "location_summary": "Phoenix, Arizona • Hollywood, Florida • Baltimore, Maryland + 7 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Hollywood", "state": "Florida" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Charlotte", "state": "North Carolina" }, { "city": "Gastonia", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT02573870" }, { "nct_id": "NCT00268723", "title": "Efficacy Study of Single-Dose Levalbuterol Tartrate HFA MDI Vs Placebo in Subjects 18 Years and Older With EIB", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Exercise-induced Bronchospasm" ], "interventions": [ { "name": "Levalbuterol tartrate HFA MDI", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sumitomo Pharma America, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 15, "start_date": "2005-12", "completion_date": "2006-02", "has_results": false, "last_update_posted_date": "2012-02-22", "last_synced_at": "2026-10-26T07:53:22.351Z", "location_count": 2, "location_summary": "Denver, Colorado • Burke, Virginia", "locations": [ { "city": "Denver", "state": "Colorado" }, { "city": "Burke", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00268723" }, { "nct_id": "NCT03958877", "title": "A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple Sclerosis", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Multiple Sclerosis, Relapsing-Remitting" ], "interventions": [ { "name": "BIIB017 (peginterferon beta-1a)", "type": "DRUG" }, { "name": "Interferon beta type 1a", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Biogen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "10 Years", "maximum_age": "18 Years", "sex": "ALL", "summary": "10 Years to 18 Years" }, "enrollment_count": 152, "start_date": "2019-10-18", "completion_date": "2027-05-20", "has_results": false, "last_update_posted_date": "2026-09-24", "last_synced_at": "2026-10-26T07:53:22.351Z", "location_count": 3, "location_summary": "La Jolla, California • Chapel Hill, North Carolina • Norfolk, Virginia", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Chapel Hill", "state": "North Carolina" }, { "city": "Norfolk", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT03958877" }, { "nct_id": "NCT00323518", "title": "A Phase II Controlled Trial of Velafermin for Prevention of Oral Mucositis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Oral Mucositis", "Stomatitis" ], "interventions": [ { "name": "velafermin", "type": "DRUG" }, { "name": "placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "CuraGen Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 390, "start_date": "2006-05", "completion_date": "2008-08", "has_results": false, "last_update_posted_date": "2016-04-13", "last_synced_at": "2026-10-26T07:53:22.351Z", "location_count": 33, "location_summary": "Little Rock, Arkansas • Berkley, California • La Jolla, California + 26 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Berkley", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT00323518" }, { "nct_id": "NCT00447473", "title": "Trial of GM-CSF Given in Combination With Ketoconazole and Mitoxantrone in Patients With Progressive Prostate Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Prostatic Neoplasms" ], "interventions": [ { "name": "GM-CSF", "type": "DRUG" }, { "name": "Ketoconazole", "type": "DRUG" }, { "name": "Mitoxantrone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "The Methodist Hospital Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 31, "start_date": "2006-07", "completion_date": "2008-09", "has_results": false, "last_update_posted_date": "2016-03-17", "last_synced_at": "2026-10-26T07:53:22.351Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00447473" }, { "nct_id": "NCT00406874", "title": "Effect of Omega 3 Fats on Sperm Quality and Sexual Function", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Infertility" ], "interventions": [ { "name": "omega 3 fats", "type": "DRUG" }, { "name": "folic acid", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Reproductive Partners Medical Group", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "35 Years", "maximum_age": "55 Years", "sex": "MALE", "summary": "35 Years to 55 Years · Male only" }, "enrollment_count": 6, "start_date": "2007-01", "completion_date": "2007-12", "has_results": false, "last_update_posted_date": "2013-06-04", "last_synced_at": "2026-10-26T07:53:22.351Z", "location_count": 1, "location_summary": "Redondo Beach, California", "locations": [ { "city": "Redondo Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00406874" }, { "nct_id": "NCT01885897", "title": "IL-15 Super Agonist ALT-803 to Treat Relapse Of Hematologic Malignancy After Allogeneic SCT", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Acute Myelogenous Leukemia (AML)", "Acute Lymphoblastic Leukemia (ALL)", "Myelodysplastic Syndromes (MDS)", "Lymphoma", "Myeloma", "Chronic Lymphocytic Leukemia (CLL)", "Chronic Myelogenous Leukemia (CML)" ], "interventions": [ { "name": "ALT-803", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Masonic Cancer Center, University of Minnesota", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 33, "start_date": "2013-11-11", "completion_date": "2020-07", "has_results": true, "last_update_posted_date": "2020-08-12", "last_synced_at": "2026-10-26T07:53:22.351Z", "location_count": 3, "location_summary": "Minneapolis, Minnesota • St Louis, Missouri • Philadelphia, Pennsylvania", "locations": [ { "city": "Minneapolis", "state": "Minnesota" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT01885897" }, { "nct_id": "NCT01270659", "title": "Safety and Efficacy Study of Fentanyl Buccal Tablet Use in the Emergency Department for Isolated Extremity Injury", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Pain" ], "interventions": [ { "name": "Fentanyl", "type": "DRUG" }, { "name": "oxycodone/acetaminophen", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Oklahoma", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 60, "start_date": "2011-05", "completion_date": "2014-10", "has_results": true, "last_update_posted_date": "2017-06-20", "last_synced_at": "2026-10-26T07:53:22.351Z", "location_count": 1, "location_summary": "Tulsa, Oklahoma", "locations": [ { "city": "Tulsa", "state": "Oklahoma" } ], "official_url": "https://clinicaltrials.gov/study/NCT01270659" } ] }